The Significance of Radiologically Detected Intramammary Lymph Nodes in Prediction of Axillary Lymph Nodes Status in Breast Cancer Patients
NCT ID: NCT05214781
Last Updated: 2022-02-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
30 participants
OBSERVATIONAL
2021-09-14
2023-03-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Nodal status in breast cancer is one of the determining factors for staging, treatment, and prognosis. Nodal status in breast cancer is one of the determining factors for staging, treatment, and prognosis. Nodal status in breast cancer is one of the determining factors for staging, treatment, and prognosis .
Intramammary lymph nodes (IMLN) are defined as a lymph nodes that should be surrounded by breast tissue in all sides, which differentiate them from those in the axillary region .
Normal IMLN are typically described in all imaging study (mammography, ultrasound and magnetic resonance imaging \[MRI\]) as a circumscribed mass, smaller than 10 mm, with oval shape and hilar fat, usually at a peripheral location, adjacent to a vein . The most common location (about 70%) is the upper outer quadrants, however, it may be located anywhere in the breast .
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Different Imaging Modalities in Regional Lymph Nodes Staging in Patients With Breast Cancer
NCT06185946
The Value of High-resolution Ultrasound in the Detection of Lymph Node Metastasis: a Proposal of NI-RADS
NCT03791840
Role of Ultrasound-Guided Lymph Node Biopsy in Axillary Staging of Breast Cancer.
NCT03681418
Axillary Staging in Node Positive Breast Cancer Patients Receiving PST. SNB vs PET/MRI
NCT04826211
The Role of Magnetic Resonance Imaging in Assessment of Axillary Lymph Nodes Metastasis in Breast Cancer Patients.
NCT03163316
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Primary outcome: prediction of axillary lymph nodes status by detection of Intramammary lymph nodes by radiological study.
* Secondary outcome: pathological correlation of molecular subtypes of breast cancer with radiological results.
Patients and Methods This is a prospective study, which will be conducted at Mansoura University Hospital from September 2021 till September 2023. This study will include thirty patients with breast cancer, after informed written consent taken from each case before being included in the study.
• Inclusion criteria included: Female patients aged more than 18 years old presented with breast cancer with radiologically detected intramammary lymph nodes and agreed to participate in the study.
• Exclusion criteria included:
1. Pregnancy.
2. Psychological instability.
3. Patients who refused to participate in our study.
4. Patients whose age less than 18 years old. \* The enrolled patients will be subjected to:
1-preoperative assessment: Detailed history and clinical breast examination.
Investigations:
Laboratory :
Complete blood picture (CBC) Liver function test Kidney function test International normalized ratio (INR)
Radiology:
Bilateral breast ultrasonography. Digital mammography for patients \> 40 years old. Breast Dynamic Contrast Enhanced and diffusion weighted magnetic resonance imaging.
5- Operative techniques: Modified radical mastectomy and conservative breast surgery with axillary clearance 6- Post-Operative follow up:
* Patient will stay in hospital for 1 to 2 days according to procedure and will be on antibiotic and analgesic according to hospital protocol.
* follow up amount and the color of fluid which discharge from drain.
* The wound is inspected after 48 h to be assessed.
* Histopathological examination of the specimen
* Immunohistochemistry will be done (estrogen receptor (ER) , progesterone receptor (PR) , HER-2neu and Ki-67 ) to determine the molecular subtypes of breast cancer
* We will correlate pathological data to radiological results.
* determine the post-operative type of systemic treatment according to pathological results.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
modified radical mastectomy
excision of the whole breast tissue including nipple and skin with axillary clearance
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Psychological instability.
* Patients who refused to participate in our study.
* Patients whose age less than 18 years old.
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mansoura University Hospital
OTHER
Mansoura University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ayman Shemes
Assistant lecturer of general surgery
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
faculty of medicine-Mansoura university - Egypt
Al Mansurah, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MD.21.09.521.R
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.